F

Fortrea Holdings Inc
NASDAQ:FTRE

Watchlist Manager
Fortrea Holdings Inc
NASDAQ:FTRE
Watchlist
Price: 19.73 USD 1.18% Market Closed
Market Cap: 1.8B USD
Have any thoughts about
Fortrea Holdings Inc?
Write Note

Fortrea Holdings Inc
Retained Earnings

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fortrea Holdings Inc
Retained Earnings Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Retained Earnings CAGR 3Y CAGR 5Y CAGR 10Y
F
Fortrea Holdings Inc
NASDAQ:FTRE
Retained Earnings
-$68.5m
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Retained Earnings
$51.4B
CAGR 3-Years
15%
CAGR 5-Years
19%
CAGR 10-Years
18%
Danaher Corp
NYSE:DHR
Retained Earnings
$43.3B
CAGR 3-Years
12%
CAGR 5-Years
10%
CAGR 10-Years
8%
Mettler-Toledo International Inc
NYSE:MTD
Retained Earnings
$8.1B
CAGR 3-Years
13%
CAGR 5-Years
14%
CAGR 10-Years
14%
Agilent Technologies Inc
NYSE:A
Retained Earnings
$773m
CAGR 3-Years
105%
CAGR 5-Years
N/A
CAGR 10-Years
-19%
IQVIA Holdings Inc
NYSE:IQV
Retained Earnings
$5.6B
CAGR 3-Years
43%
CAGR 5-Years
42%
CAGR 10-Years
N/A
No Stocks Found

Fortrea Holdings Inc
Glance View

Market Cap
1.8B USD
Industry
Life Sciences Tools & Services

Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 19,000 full-time employees. The company went IPO on 2023-06-16. The firm is a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, patient access solutions and other enabling services. The Company’s segments include Clinical Services and Enabling Services. The Company’s global solutions include Clinical Development, Clinical Pharmacology, Drug Development Consulting Services, Device and Diagnostic Development, and Full and Functional Service Provider Models, among others. Its Clinical Development solutions include Early: Phase I/II a, Late: Phase II b/III, Real-World Evidence and Post-Approval Studies, Decentralized Clinical Trials, Data Analysis and Reporting, Clinical Trial Project Management and Monitoring, and Patient Safety and Pharmacovigilance. By therapeutic or specialty areas, it has scientific expertise in cardiovascular, cell and gene therapies, dermatology, diabetes and endocrinology, hepatology, infectious disease, and others.

FTRE Intrinsic Value
31.53 USD
Undervaluation 37%
Intrinsic Value
Price
F

See Also

What is Fortrea Holdings Inc's Retained Earnings?
Retained Earnings
-68.5m USD

Based on the financial report for Dec 31, 2023, Fortrea Holdings Inc's Retained Earnings amounts to -68.5m USD.

What is Fortrea Holdings Inc's Retained Earnings growth rate?
Retained Earnings CAGR 3Y
17%

Over the last year, the Retained Earnings growth was 75%. The average annual Retained Earnings growth rates for Fortrea Holdings Inc have been 17% over the past three years .

Back to Top